Abstract
(Chemical Presented) A potential anti-SARS drug has been developed by dynamic ligation screening (DLS), by which nucleophilic fragments are directed to the protein's active site by reversible reaction with an aldehyde inhibitor. Their inhibitory effect is detected by competition with a fluorogenic enzyme substrate. With this concept, low-affinity fragments binding specifically to the active site are quickly identified in a functional enzyme assay.
| Original language | English |
|---|---|
| Journal | Angewandte Chemie - International Edition |
| Volume | 47 |
| Issue number | 17 |
| Pages (from-to) | 3275-3278 |
| Number of pages | 4 |
| ISSN | 1433-7851 |
| DOIs | |
| Publication status | Published - 14.04.2008 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Research Areas and Centers
- Academic Focus: Center for Infection and Inflammation Research (ZIEL)
Coronavirus related work
- Research on SARS-CoV-2 / COVID-19
Fingerprint
Dive into the research topics of 'Sensitized detection of inhibitory fragments and iterative development of non-peptidic protease inhibitors by dynamic ligation screening'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver